{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:51:55Z","timestamp":1793875915228,"version":"4.7.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00756-7","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T06:19:29Z","timestamp":1713421169000},"page":"938-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2688-0603","authenticated-orcid":false,"given":"Sanju","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahulsimham","family":"Vegesna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9807-7994","authenticated-orcid":false,"given":"Sumit","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-721X","authenticated-orcid":false,"given":"Ashwin V.","family":"Kammula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-6757","authenticated-orcid":false,"given":"Saugato Rahman","family":"Dhruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-067X","authenticated-orcid":false,"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-8341","authenticated-orcid":false,"given":"D. Lucas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-0329","authenticated-orcid":false,"given":"Nishanth Ulhas","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg V.","family":"Stroganov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Grishagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-7550","authenticated-orcid":false,"given":"Kenneth D.","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-3651","authenticated-orcid":false,"given":"Collin M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-5486","authenticated-orcid":false,"given":"Peng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":false,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-9707","authenticated-orcid":false,"given":"Cyril H.","family":"Benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-4128","authenticated-orcid":false,"given":"Trever G.","family":"Bivona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-8033","authenticated-orcid":false,"given":"Alejandro A.","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7862-3940","authenticated-orcid":false,"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"756_CR1","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"756_CR2","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.patter.2021.100328","volume":"2","author":"K Huang","year":"2021","unstructured":"Huang, K., Xiao, C., Glass, L. M. & Critchlow, C. M. Machine learning applications for therapeutic tasks with genomics data. Patterns 2, 100328 (2021).","journal-title":"Patterns"},{"key":"756_CR3","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/2159-8290.CD-21-0090","volume":"11","author":"B Bhinder","year":"2021","unstructured":"Bhinder, B., Gilvary, C., Madhukar, N. S. & Elemento, O. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 11, 900\u2013915 (2021).","journal-title":"Cancer Discov."},{"key":"756_CR4","first-page":"83","volume":"18","author":"N Singla","year":"2020","unstructured":"Singla, N. & Singla, S. Harnessing big data with machine learning in precision oncology. Kidney Cancer J. 18, 83\u201384 (2020).","journal-title":"Kidney Cancer J."},{"key":"756_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.molmed.2017.08.003","volume":"23","author":"D Senft","year":"2017","unstructured":"Senft, D., Leiserson, M. D. M., Ruppin, E. & Ronai, Z. Precision oncology: the road ahead. Trends Mol. Med. 23, 874\u2013898 (2017).","journal-title":"Trends Mol. Med."},{"key":"756_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2020.09.007","volume":"84","author":"AM Tsimberidou","year":"2022","unstructured":"Tsimberidou, A. M., Fountzilas, E., Bleris, L. & Kurzrock, R. Transcriptomics and solid tumors: the next frontier in precision cancer medicine. Semin. Cancer Biol. 84, 50\u201359 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"756_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531\u2013548 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"756_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71\u201388 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"756_CR9","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3390\/cancers12103065","volume":"12","author":"N Sawabata","year":"2020","unstructured":"Sawabata, N. Circulating tumor cells: from the laboratory to the cancer clinic. Cancers 12, 3065 (2020).","journal-title":"Cancers"},{"key":"756_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","volume":"37","author":"N Beaubier","year":"2019","unstructured":"Beaubier, N. et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat. Biotechnol. 37, 1351\u20131360 (2019).","journal-title":"Nat. Biotechnol."},{"key":"756_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43018-019-0010-1","volume":"1","author":"A Hayashi","year":"2020","unstructured":"Hayashi, A. et al. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat. Cancer 1, 59\u201374 (2020).","journal-title":"Nat. Cancer"},{"key":"756_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751\u2013758 (2019).","journal-title":"Nat. Med."},{"key":"756_CR13","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1158\/1078-0432.CCR-17-3431","volume":"24","author":"M Tanioka","year":"2018","unstructured":"Tanioka, M. et al. Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer. Clin. Cancer Res. 24, 5292\u20135304 (2018).","journal-title":"Clin. Cancer Res."},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"e1913968","DOI":"10.1001\/jamanetworkopen.2019.13968","volume":"2","author":"OM Vaske","year":"2019","unstructured":"Vaske, O. M. et al. Comparative tumor RNA sequencing analysis for difficult-to-treat pediatric and young adult patients with cancer. JAMA Netw. Open 2, e1913968 (2019).","journal-title":"JAMA Netw. Open"},{"key":"756_CR15","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong, M. et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat. Med. 26, 1742\u20131753 (2020).","journal-title":"Nat. Med."},{"key":"756_CR16","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","volume":"184","author":"JS Lee","year":"2021","unstructured":"Lee, J. S. et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell 184, 2487\u20132502 (2021).","journal-title":"Cell"},{"key":"756_CR17","doi-asserted-by":"crossref","unstructured":"Dinstag, G. et al. Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med 4, 15\u201330.e8 (2023).","DOI":"10.1016\/j.medj.2022.11.001"},{"key":"756_CR18","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/2159-8290.CD-20-1376","volume":"11","author":"LNG Castro","year":"2021","unstructured":"Castro, L. N. G., Tirosh, I. & Suv\u00e0, M. L. Decoding cancer biology one cell at a time. Cancer Discov. 11, 960\u2013970 (2021).","journal-title":"Cancer Discov."},{"key":"756_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00168-1","volume":"5","author":"GE Wensink","year":"2021","unstructured":"Wensink, G. E. et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. npj Precis. Oncol. 5, 30 (2021).","journal-title":"npj Precis. Oncol."},{"key":"756_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao, Y. et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26, 17\u201326 (2020).","journal-title":"Cell Stem Cell"},{"key":"756_CR21","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","volume":"31","author":"CJ de Witte","year":"2020","unstructured":"de Witte, C. J. et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses. Cell Rep. 31, 107762 (2020).","journal-title":"Cell Rep."},{"key":"756_CR22","doi-asserted-by":"publisher","first-page":"eaan4730","DOI":"10.1126\/scitranslmed.aan4730","volume":"9","author":"AK Shalek","year":"2017","unstructured":"Shalek, A. K. & Benson, M. Single-cell analyses to tailor treatments. Sci. Transl. Med. 9, eaan4730 (2017).","journal-title":"Sci. Transl. Med."},{"key":"756_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0122-1","volume":"4","author":"G Adam","year":"2020","unstructured":"Adam, G. et al. Machine learning approaches to drug response prediction: challenges and recent progress. npj Precis. Oncol. 4, 19 (2020).","journal-title":"npj Precis. Oncol."},{"key":"756_CR24","doi-asserted-by":"publisher","first-page":"53763","DOI":"10.18632\/oncotarget.17893","volume":"8","author":"S Zhu","year":"2017","unstructured":"Zhu, S. et al. Advances in single-cell RNA sequencing and its applications in cancer research. Oncotarget 8, 53763\u201353779 (2017).","journal-title":"Oncotarget"},{"key":"756_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0945-9","volume":"17","author":"KT Kim","year":"2016","unstructured":"Kim, K. T. et al. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol. 17, 80 (2016).","journal-title":"Genome Biol."},{"key":"756_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-01000-y","volume":"13","author":"C Suphavilai","year":"2021","unstructured":"Suphavilai, C. et al. Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures. Genome Med. 13, 189 (2021).","journal-title":"Genome Med."},{"key":"756_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-01001-x","volume":"13","author":"C Fustero-Torre","year":"2021","unstructured":"Fustero-Torre, C. et al. Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Med. 13, 187 (2021).","journal-title":"Genome Med."},{"key":"756_CR28","doi-asserted-by":"publisher","first-page":"eab4038","DOI":"10.1126\/sciadv.abe4038","volume":"7","author":"A Ianevski","year":"2021","unstructured":"Ianevski, A. et al. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Sci. Adv. 7, eab4038 (2021).","journal-title":"Sci. Adv."},{"key":"756_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491\u2013503 (2021).","journal-title":"Nat. Med."},{"key":"756_CR30","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"756_CR31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 (2018).","journal-title":"Cell"},{"key":"756_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"756_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 (2017).","journal-title":"Cell"},{"key":"756_CR34","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","volume":"52","author":"GS Kinker","year":"2020","unstructured":"Kinker, G. S. et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat. Genet. 52, 1208\u20131218 (2020).","journal-title":"Nat. Genet."},{"key":"756_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","volume":"12","author":"D Plana","year":"2022","unstructured":"Plana, D., Palmer, A. C. & Sorger, P. K. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 12, 606\u2013624 (2022).","journal-title":"Cancer Discov."},{"key":"756_CR36","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucl. Acids Res. 41, D955\u2013D961 (2012).","journal-title":"Nucl. Acids Res."},{"key":"756_CR37","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","volume":"5","author":"B Seashore-Ludlow","year":"2015","unstructured":"Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210\u20131223 (2015).","journal-title":"Cancer Discov."},{"key":"756_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235\u2013248 (2020).","journal-title":"Nat. Cancer"},{"key":"756_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39528-9","volume":"14","author":"NU Nair","year":"2023","unstructured":"Nair, N. U. et al. A landscape of response to drug combinations in non-small-cell lung cancer. Nat. Commun. 14, 3830 (2023).","journal-title":"Nat. Commun."},{"key":"756_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","volume":"2","author":"JI Griffiths","year":"2021","unstructured":"Griffiths, J. I. et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4\/6 therapy. Nat. Cancer 2, 658\u2013671 (2021).","journal-title":"Nat. Cancer"},{"key":"756_CR41","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232\u20131251 (2020).","journal-title":"Cell"},{"key":"756_CR42","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","volume":"12","author":"A Noronha","year":"2022","unstructured":"Noronha, A. et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 12, 2666\u20132683 (2022).","journal-title":"Cancer Discov."},{"key":"756_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","volume":"15","author":"KM Pluchino","year":"2012","unstructured":"Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R. & Gottesman, M. M. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98\u2013105 (2012).","journal-title":"Drug Resist. Updat."},{"key":"756_CR44","doi-asserted-by":"crossref","unstructured":"Bartholomeusz, C. et al. Gemcitabine overcomes erlotinib resistance in EGFR-overexpressing cancer cells through downregulation of Akt. J. Cancer 2, 435\u2013442 (2011).","DOI":"10.7150\/jca.2.435"},{"key":"756_CR45","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960\u20131966 (2007).","journal-title":"J. Clin. Oncol."},{"key":"756_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2482-z","volume":"16","author":"S Shin","year":"2016","unstructured":"Shin, S., Park, C. M., Kwon, H. & Lee, K.-H. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer 16, 443 (2016).","journal-title":"BMC Cancer"},{"key":"756_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1200\/PO.20.00315","volume":"5","author":"J Luo","year":"2021","unstructured":"Luo, J. et al. Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor. JCO Precis. Oncol. 5, 55\u201364 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"756_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","volume":"103","author":"AB Mariotto","year":"2011","unstructured":"Mariotto, A. B. et al. Projections of the cost of cancer care in the United States: 2010\u20132020. J. Natl. Cancer Inst. 103, 117\u2013128 (2011).","journal-title":"J. Natl. Cancer Inst."},{"key":"756_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41587-019-0379-5","volume":"38","author":"V Svensson","year":"2020","unstructured":"Svensson, V. Droplet scRNA-seq is not zero-inflated. Nat. Biotech. 38, 147\u2013150 (2020).","journal-title":"Nat. Biotech."},{"key":"756_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41587-020-00810-6","volume":"39","author":"Y Cao","year":"2021","unstructured":"Cao, Y., Kitanovski, S., K\u00fcppers, R. & Hoffmann, D. UMI or not UMI, that is the question for scRNA-seq zero-inflation. Nat. Biotechnol. 39, 158\u2013159 (2021).","journal-title":"Nat. Biotechnol."},{"key":"756_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Soft. 33, 1\u201322 (2010).","journal-title":"J. Stat. Soft."},{"key":"756_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19563-6","volume":"11","author":"A Ling","year":"2020","unstructured":"Ling, A. & Huang, R. S. Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action. Nat. Commun. 11, 5848 (2020).","journal-title":"Nat. Commun."},{"key":"756_CR53","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"756_CR54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2168479018782885","volume":"53","author":"S Stergiopoulos","year":"2019","unstructured":"Stergiopoulos, S., Getz, K. A. & Blazynski, C. Evaluating the completeness of ClinicalTrials.gov. Ther. Innov. Regul. Sci. 53, 307\u2013317 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"756_CR55","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","volume":"24","author":"D Lambrechts","year":"2018","unstructured":"Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277\u20131289 (2018).","journal-title":"Nat. Med."},{"key":"756_CR56","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1002\/cam4.2113","volume":"8","author":"Q Song","year":"2019","unstructured":"Song, Q. et al. Dissecting intratumoral myeloid cell plasticity by single cell RNA\u2010seq. Cancer Med. 8, 3072\u20133085 (2019).","journal-title":"Cancer Med."},{"key":"756_CR57","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317\u20131334 (2019).","journal-title":"Immunity"},{"key":"756_CR58","doi-asserted-by":"publisher","unstructured":"Sinha, S. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors (0.1) [Data set]. Zenodo https:\/\/doi.org\/10.5281\/zenodo.7860559 (2022).","DOI":"10.5281\/zenodo.7860559"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00756-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:05:36Z","timestamp":1719428736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00756-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00756-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1641376\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S., R.V., A.A.S. and E.R. are inventors on a provisional patent application covering the methods in PERCEPTION. E.R. is a co-founder of Medaware, Metabomed and Pangea Biomed (divested from the latter). E.R. serves as a non-paid scientific consultant to Pangea Biomed, a company developing a precision oncology SL-based multi-omics approach, with emphasis on bulk tumor transcriptomics. T.G.B. is an advisor to Array\/Pfizer, Revolution Medicines, Springworks, Jazz Pharmaceuticals, Relay Therapeutics, Rain Therapeutics and Engine Biosciences, and receives research funding from Novartis, Strategia, Kinnate and Revolution Medicines. The work in the laboratory of C.H.B. was funded in part by Amgen and Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}